Stem Cell Therapy for Neurogenic Bladder Dysfunction in Rodent Models: A Systematic Review

Abstract

Purpose: Neurogenic bladder dysfunction (NGB) has an impact on the quality of life, which made it an important research subject in preclinical studies. The present review investigates the effect of stem cell (SC) therapy on bladder functional recovery after the onset of spinal cord injury (SCI), multiple sclerosis (MS), Parkinson disease (PD), and stroke in rodent models.Methods: All experiments evaluated the regenerative potential of SC on the management of NGB in rodent models up to June 2019, were included. From 1,189 relevant publications, 20 studies met our inclusion criteria of which 15 were conducted on SCI, 2 on PD, 2 on stroke, and 1 on MS in the rodent models. We conducted a meta-analysis on SCI experiments and for other neurological diseases, detailed urodynamic findings were reported.Results: The common SC sources used for therapeutical purposes were neural progenitor cells, bone marrow mesenchymal SCs, human amniotic fluid SCs, and human umbilical cord blood SCs. There was a significant improvement of micturition pressure in both contusion and transaction SCI models 4 and 8 weeks post-SC transplantation. Residual urine volume, micturition volume, and bladder capacity were improved 28 days after SC transplantation only in the transaction model of SCI. Nonvoiding contraction recovered only in 56 days post-cell transplantation in the contusion model.Conclusions: Partial bladder recovery has been evident after SC therapy in SCI models. Due to limitations in the number of studies in other neurological diseases, additional studies are necessary to confirm the detailed mechanism for bladder recovery.

Progress and research trends in neurogenic bladder after spinal cord injury bibliometric analysis based on web of science database: An observational study

“…Mesenchymal stem cells (MSCs) were also found to inhibit fibrosis via the TGF-beta 1 signaling pathway. [37] Adipose tissue-derived mesenchymal stem cells (AT-MSCs) were studied for smooth muscle cell (SMC) differentiation on scaffolds and tissue culture polystyrene (TCPS) surfaces. This biofunctional scaffold aims to repair and regenerate bladder tissues and promote the restoration of NB (NGB) function through the multidirectional differentiation potential of stem cells.…”

“…Mesenchymal stem cells (MSCs) were also found to inhibit fibrosis via the TGF-beta 1 signaling pathway. [ 37 ]…”

Tissue Engineering and Stem Cell Therapy in Neurogenic Bladder Dysfunction: Current and Future Perspectives

“…Similarly, according to a systematic review on stem cell therapy for NBD in rodent models published in 2020, out of 20 studies eligible for review, 15 were conducted on SCI, 2 were conducted on PD, 2 were conducted on stroke, and 1 was conducted on MS [ 44 ]. The review concluded that the common SC sources used for therapeutical purposes were neural progenitor cells, bone marrow mesenchymal SCs, human amniotic fluid SCs, and human umbilical cord blood SCs.…”

Gap Junction–Mediated Transport of Metabolites Between Stem Cells and Vascular Endothelial Cells

“…However, the selectivity or priority of the molecules that actually pass through the gap junctions has not been clarified. Cell–cell communication and signaling are regulated by the exchange of small soluble molecules between cells through gap junction channels 13 . This exchange between stem cells and vascular endothelial cells via gap junctions is important for both HSCs and MSCs in cell therapies after stroke 14 , 15 .…”

“…With the recent development of stem cell research, cell therapy has been studied as a new therapeutic strategy for various diseases [1][2][3][4][5][6][7][8][9][10][11][12][13] . Hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are major cell sources in cell-based therapies.…”